Trinity Biotech (TRIB) Registration filing summary

Company overview and business model

• Commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors.

• Develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical labs, recently expanding into wearable biosensors with the acquisition of Waveform Technologies assets.

• Products detect infectious diseases and quantify biomarkers like Haemoglobin A1c; sold directly in the US, Brazil, UK, Germany, France, and via distributors in ~100 countries.

Financial performance and metrics

• As of December 31, 2025: cash and cash equivalents of $5.1M (actual), $7.6M (adjusted); total debt $124.6M (actual), $130.9M (adjusted).

• Shareholders' equity was $(72.0)M, with total capitalization of $52.6M (actual) and $58.9M (adjusted).

• Outstanding options, warrants, and convertible notes could further dilute equity.

Use of proceeds and capital allocation

• No proceeds will be received from the sale of ADSs by selling shareholders; conversions reduce outstanding debt obligations.

• Company bears registration and issuance costs; selling shareholders pay their own transaction expenses.